Calbindin as A Potential Drug Target for Neurological Disorders
Calbindin as A Potential Drug Target for Neurological Disorders
CALB1 (D-28K), a protein found in the brain, has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders. Its function in neural development, maintenance, and regulation has also been implicated in several neurological conditions, making it an attractive target for researchers and pharmaceutical companies.
Calbindin (CALB1) is a protein that is expressed in various tissues throughout the body, including the brain. Its primary function is to localize and regulate the distribution of calcium ions in the brain, which are essential for neurotransmitter function and neural communication. The regulation of calcium ions is a critical process in neural development, maintenance, and behavior, and alterations in this process have been implicated in several neurological and psychiatric disorders.
Research has shown that disruptions in the regulation of calcium ions can lead to the development of neurological and psychiatric disorders. For example, individuals with schizophrenia have been found to have reduced levels of the protein Calbindin in their brains compared to healthy individuals. Similarly, individuals with Alzheimer's disease have been shown to have increased levels of the protein in their brains compared to healthy individuals.
In addition to its role in neural development and maintenance, Calbindin has also been implicated in the regulation of various signaling pathways that are involved in neurological function. For example, the protein has been shown to be involved in the regulation of neurotransmitter release from axons in the brain, which is critical for communication between neurons. Similarly, the protein has been shown to be involved in the regulation of the growth and differentiation of neural stem cells, which are important for the development and maintenance of the nervous system.
Given the significant impact of Calbindin on neural development, maintenance, and behavior, it is a promising target for drug development. Research has shown that various drugs that have been developed to treat neurological and psychiatric disorders have the potential to alter the levels of Calbindin in the brain. For example, drugs that have been shown to treat Alzheimer's disease, such as Continue reading
Protein Name: Calbindin 1
Functions: Buffers cytosolic calcium. May stimulate a membrane Ca(2+)-ATPase and a 3',5'-cyclic nucleotide phosphodiesterase
More Common Targets
CALB2 | CALCA | CALCB | Calcium channel | Calcium release-activated channel (CRAC) | Calcium-activated chloride channel regulators | Calcium-Activated K(Ca) Potassium Channel | CALCOCO1 | CALCOCO2 | CALCR | CALCRL | CALCRL-AS1 | CALD1 | CALHM1 | CALHM2 | CALHM3 | CALHM4 | CALHM5 | CALHM6 | CALM1 | CALM2 | CALM2P1 | CALM2P2 | CALM3 | CALML3 | CALML3-AS1 | CALML4 | CALML5 | CALML6 | Calmodulin | CALN1 | Calpain | Calpain-13 | Calprotectin | CALR | CALR3 | CALU | CALY | CAMK1 | CAMK1D | CAMK1G | CAMK2A | CAMK2B | CAMK2D | CAMK2G | CAMK2N1 | CAMK2N2 | CAMK4 | CAMKK1 | CAMKK2 | CAMKMT | CAMKV | CAMLG | CAMP | cAMP Phosphodiesterase | cAMP Responsive Element Binding Protein (CREB) | cAMP-Dependent protein kinase (PKA) | CAMSAP1 | CAMSAP2 | CAMSAP3 | CAMTA1 | CAMTA2 | CAND1 | CAND1.11 | CAND2 | Cannabinoid receptor | CANT1 | CANX | Cap-binding complex | CAP1 | CAP2 | CAPG | CAPN1 | CAPN10 | CAPN10-DT | CAPN11 | CAPN12 | CAPN13 | CAPN14 | CAPN15 | CAPN2 | CAPN3 | CAPN5 | CAPN6 | CAPN7 | CAPN8 | CAPN9 | CAPNS1 | CAPNS2 | CAPRIN1 | CAPRIN2 | CAPS | CAPS2 | CAPSL | CAPZA1 | CAPZA2 | CAPZA3 | CAPZB | Carbonic Anhydrase | Carbonic Anhydrase V